VOL. XCIV, NO. 247
★ WIDE MOAT STOCKS COMPARISON ★
NO ADVICE
Tuesday, December 30, 2025
Stock Comparison
Agilent Technologies, Inc. vs Gilead Sciences, Inc.
Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.
Agilent Technologies, Inc.
A · New York Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Agilent Technologies, Inc.'s moat claims, evidence, and risks.
View A analysisGilead Sciences, Inc.
GILD · NASDAQ Global Select Market
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Gilead Sciences, Inc.'s moat claims, evidence, and risks.
View GILD analysisComparison highlights
- Moat score gap: Gilead Sciences, Inc. leads (74 / 100 vs 65 / 100 for Agilent Technologies, Inc.).
- Segment focus: Agilent Technologies, Inc. has 3 segments (41.9% in Agilent CrossLab); Gilead Sciences, Inc. has 5 segments (68.5% in HIV).
- Primary market structure: Competitive vs Oligopoly. Pricing power: Strong vs Moderate.
- Moat breadth: Agilent Technologies, Inc. has 5 moat types across 2 domains; Gilead Sciences, Inc. has 8 across 3.
Primary market context
Agilent Technologies, Inc.
Agilent CrossLab
Laboratory services, compliance/maintenance, consumables and lab informatics across the lab workflow
Global
B2B (installed base labs across pharma, diagnostics, academia and applied markets)
Aftermarket services + consumables + informatics
41.9%
Gilead Sciences, Inc.
HIV
HIV treatment and prevention medicines (antiretroviral therapy and PrEP)
Global (U.S. and Europe are major markets)
Patients/prescribers; reimbursed by public and private payers; distributed via wholesalers and specialty pharmacies
Drug developer and marketing authorization holder
68.5%
Side-by-side metrics
Moat coverage
Shared moat types
Agilent Technologies, Inc. strengths
Gilead Sciences, Inc. strengths
Segment mix
Agilent Technologies, Inc. segments
Full profile >Life Sciences and Diagnostics Markets
Oligopoly
Agilent CrossLab
Competitive
Applied Markets
Oligopoly
Gilead Sciences, Inc. segments
Full profile >HIV
Oligopoly
Oncology (Cell Therapy + Trodelvy)
Oligopoly
Liver Disease
Oligopoly
Veklury (Remdesivir)
Competitive
Other Products
Competitive
Want the full wide moat stocks list?
Browse the full ranking of wide moat stocks, updated with moat scores and segment context.
View the moat stocks listCuration & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.